{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:25:22Z","timestamp":1794583522751,"version":"4.9.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.seminoncol.2026.152563","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:55:18Z","timestamp":1790175318000},"page":"152563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-0339","authenticated-orcid":false,"given":"Tarun Kumar","family":"Suvvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar VNS","family":"Kocharlakota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jashika","family":"Mellamputi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamini Subha LR","family":"Siripurapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Menda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teja","family":"Sureddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykrishna","family":"Ghatamaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Veggalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataramana","family":"Kandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Sarma Jayant","family":"Tetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/gutjnl-2024-333227","article-title":"Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021","volume":"74","author":"Danpanichkul","year":"2025","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0003","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jare.2025.11.051","article-title":"Burden profiles and mortality-attributable risk factors for gastrointestinal cancers: a comprehensive analysis, 1990-2021","volume":"86","author":"Fan","year":"2026","journal-title":"J Adv Res"},{"issue":"11-12","key":"10.1016\/j.seminoncol.2026.152563_bib0004","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/1751-2980.70026","article-title":"Global burden and trends of early-onset gastrointestinal cancers from 1990 to 2021","volume":"26","author":"Wang","year":"2025","journal-title":"J Dig Dis"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-023-03183-3","article-title":"Immune checkpoint inhibitors in gastrointestinal malignancies: an umbrella review","volume":"24","author":"Noori","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0007","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0008","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0009","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.2010.226092","article-title":"Stromal biology and therapy in pancreatic cancer","volume":"60","author":"Neesse","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PPO.0000000000000140","article-title":"Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction","volume":"21","author":"Whatcott","year":"2015","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/1878-0261.12018","article-title":"Determinants of metastatic competency in colorectal cancer","volume":"11","author":"Tauriello","year":"2017","journal-title":"Mol Oncol"},{"issue":"7517","key":"10.1016\/j.seminoncol.2026.152563_bib0012","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0013","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152563_bib0014","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","article-title":"Immunological landscape and immunotherapy of hepatocellular carcinoma","volume":"12","author":"Prieto","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152563_bib0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0016","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.cell.2019.01.051","article-title":"SnapShot: cancer immunotherapy with oncolytic viruses","volume":"176","author":"Gujar","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2025.200333","article-title":"Oncolytic virus and immunogenic cell death in cancer therapy","volume":"20","author":"Cao","year":"2025","journal-title":"Tumour Virus Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0019","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/mt.2015.156","article-title":"Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses","volume":"24","author":"Rajani","year":"2016","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0020","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0021","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0022","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0023","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0026","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0027","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers10060160","article-title":"A phase II study of Pelareorep (REOLYSIN\u00ae) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma","volume":"10","author":"Mahalingam","year":"2018","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003255","article-title":"Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152563_bib0029","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152563_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0031","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0032","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae200","article-title":"Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer","volume":"30","author":"Runcie","year":"2025","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006561","article-title":"Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced\/metastatic epithelial cancer: a phase I clinical trial (SPICE)","volume":"11","author":"Fakih","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0034","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/1535-7163.MCT-19-1117","article-title":"Elucidation of Pelareorep pharmacodynamics in A phase I trial in patients with KRAS-mutated colorectal cancer","volume":"19","author":"Goel","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0036","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/mt.2014.194","article-title":"First-in-man study of Western Reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity","volume":"23","author":"Zeh","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152563_bib0037","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","article-title":"Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers","volume":"24","author":"Downs-Canner","year":"2016","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152563_bib0038","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-24-2498","article-title":"A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer","volume":"31","author":"West","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0039","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000533650","article-title":"PHOCUS: a phase 3, randomized, open-label study of sequential treatment with Pexa-Vec (JX-594) and Sorafenib in patients with advanced hepatocellular carcinoma","volume":"13","author":"Abou-Alfa","year":"2023","journal-title":"Liver Cancer"},{"issue":"8062","key":"10.1016\/j.seminoncol.2026.152563_bib0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","article-title":"Oncolytic virus VG161 in refractory hepatocellular carcinoma","volume":"641","author":"Shen","year":"2025","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152563_bib0041","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-0244","article-title":"Phase I study of oncolytic Vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis","volume":"24","author":"Lauer","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.seminoncol.2026.152563_bib0042","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e14553","article-title":"Phase I study of oncolytic adenovirus BioTTT001 in patients with peritoneal carcinomatosis","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0043","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0044","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/cgt.2010.65","article-title":"A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer","volume":"18","author":"Nakao","year":"2011","journal-title":"Cancer Gene Ther"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152563_bib0046","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"AI Zheng"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6230","key":"10.1016\/j.seminoncol.2026.152563_bib0048","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0049","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","article-title":"Cancer-associated fibroblasts in gastrointestinal cancer","volume":"16","author":"Kobayashi","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/cancers13020183","article-title":"Fibroblast subsets in intestinal homeostasis, carcinogenesis, tumor progression, and metastasis","volume":"13","author":"Dang","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0051","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12964-025-02516-1","article-title":"Cancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance","volume":"23","author":"Lu","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1703211","article-title":"Regulatory T cells in cancer: from immunosuppression to therapeutic targeting","volume":"16","author":"Basurto-Olvera","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152563_bib0053","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0054","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/cac2.12156","article-title":"The role of myeloid-derived suppressor cells in gastrointestinal cancer","volume":"41","author":"Cui","year":"2021","journal-title":"Cancer Commun"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0056","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/IJN.S502833","article-title":"Localized drug delivery in different gastrointestinal cancers: navigating challenges and advancing nanotechnological solutions","volume":"20","author":"Hasan","year":"2025","journal-title":"Int J Nanomed"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0057","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/pharmaceutics15061664","article-title":"Anatomical targeting of anticancer drugs to solid tumors using specific administration routes: review","volume":"15","author":"Saito","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0058","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/cancers17010089","article-title":"Endoscopic ultrasound-guided treatments for pancreatic cancer: understanding how endoscopic ultrasound has revolutionized management of pancreatic cancer","volume":"17","author":"Singh","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v2010078","article-title":"Oncolytic viruses for cancer therapy: overcoming the obstacles","volume":"2","author":"Wong","year":"2010","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152563_bib0060","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0061","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.03.003","article-title":"Intraperitoneal oncolytic virotherapy for patients with malignant ascites: characterization of clinical efficacy and antitumor immune response","volume":"25","author":"Zhang","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"24","key":"10.1016\/j.seminoncol.2026.152563_bib0062","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: challenges and considerations in an evolving clinical landscape","volume":"18","author":"Lauer","year":"2022","journal-title":"Future Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152563_bib0063","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0064","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0066","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2021.05.009","article-title":"Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation","volume":"22","author":"Farrera-Sal","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0067","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152563_bib0068","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-021-01075-5","article-title":"Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies","volume":"14","author":"Heidbuechel","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152563_bib0069","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008431","article-title":"An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152563_bib0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0071","first-page":"193","article-title":"Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art","volume":"4","author":"Nande","year":"2015","journal-title":"Oncolytic Virother"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152563_bib0072","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1016\/j.ymthe.2026.05.007","article-title":"Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors","volume":"34","author":"Jirovec","year":"2026","journal-title":"Mol Ther"},{"issue":"110","key":"10.1016\/j.seminoncol.2026.152563_bib0073","doi-asserted-by":"crossref","DOI":"10.3791\/53757","article-title":"Transarterial administration of oncolytic viruses for locoregional therapy of orthotopic HCC in rats","author":"Altomonte","year":"2016","journal-title":"J Vis Exp"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0074","first-page":"47","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107437","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia","volume":"94","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0076","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001684","article-title":"Mesenchymal stem cells and oncolytic viruses: joining forces against cancer","volume":"9","author":"Moreno","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"40","key":"10.1016\/j.seminoncol.2026.152563_bib0077","doi-asserted-by":"crossref","DOI":"10.1002\/advs.75406","article-title":"Engineering oncolytic virus-armed macrophages for enhanced cancer immunotherapy","volume":"13","author":"Wang","year":"2026","journal-title":"Adv Sci"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0078","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2026.124143","article-title":"Coated oncolytic viruses based \u201cdouble strike\u201d strategy triggering CD19 CAR-T therapy in gastrointestinal tumors","volume":"332","author":"Zhang","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0080","article-title":"The combination therapy of oncolytic virotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152563_bib0081","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152563_bib0082","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99573","article-title":"Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses","volume":"3","author":"Watanabe","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0083","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CAR-T cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumors","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02103","article-title":"Oncolytic viruses partner with T-cell therapy for solid tumor treatment","volume":"9","author":"Rosewell Shaw","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0086","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer","volume":"25","author":"Matuszewska","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0087","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0088","doi-asserted-by":"crossref","first-page":"17","DOI":"10.20517\/2394-4722.2021.212","article-title":"Combining oncolytic virus and radiation therapy for cancer management","volume":"8","author":"Jayalie","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152563_bib0089","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-05-0309","article-title":"Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma","volume":"11","author":"Yu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105219","article-title":"Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures","volume":"105","author":"Sch\u00e4fer","year":"2024","journal-title":"eBioMedicine"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152563_bib0091","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.18632\/oncotarget.26679","article-title":"Interferon signaling predicts response to oncolytic virotherapy","volume":"10","author":"Kurokawa","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0092","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010662","article-title":"Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia\/Ib trial results and biomarker insights","volume":"13","author":"Wang","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152563_bib0093","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1158\/0008-5472.CAN-13-3472","article-title":"Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability","volume":"74","author":"Kuruppu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0094","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/mto.2014.7","article-title":"Molecular imaging of oncolytic viral therapy","volume":"1","author":"Haddad","year":"2014","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0095","article-title":"Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0096","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trecan.2018.11.005","article-title":"Ushering in integrated T cell repertoire profiling in cancer","volume":"5","author":"Jiang","year":"2019","journal-title":"Trends Cancer"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152563_bib0097","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.3390\/ijms23158590","article-title":"T-cell receptor repertoire sequencing and its applications: focus on infectious diseases and cancer","volume":"23","author":"Mazzotti","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0098","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004462","article-title":"The use of oncolytic virotherapy in the neoadjuvant setting","volume":"10","author":"Thomas","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152563_bib0099","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-022-01681-x","article-title":"Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery","volume":"28","author":"Marron","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5114\/pjr.2023.125027","article-title":"Diagnosis and treatment of peritoneal carcinomatosis - a comprehensive overview","volume":"88","author":"Szadkowska","year":"2023","journal-title":"Pol J Radiol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.835300","article-title":"Oncolytic virotherapy in peritoneal metastasis gastric cancer: the challenges and achievements","volume":"9","author":"Shao","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152563_bib0102","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152563_bib0103","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat Protoc"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152563_bib0104","article-title":"Heating it up: oncolytic viruses make tumors \u2018hot\u2019 and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152563_bib0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Apolonio","year":"2021","journal-title":"World J Virol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152563_bib0106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2023","journal-title":"J Neurosurg"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152563_bib0107","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12032-025-02746-w","article-title":"The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches","volume":"42","author":"Sheikh","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.seminoncol.2026.152563_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101530","article-title":"Current landscape and perspective of oncolytic viruses and their combination therapies","volume":"25","author":"Su","year":"2022","journal-title":"Transl Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426001089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426001089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:29:53Z","timestamp":1794580193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0093775426001089"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152563","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic viruses in gastrointestinal malignancies: Clinical progress, translational challenges, and future directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152563"}}